← Back to Search

Working Memory Training for Parkinson's Disease (PDWM Trial)

N/A

Waitlist Available

Led By Stephanie Jones, PhD

Research Sponsored by Gail Eskes

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Clinical diagnosis of idiopathic Parkinson's disease

Be classified as Hohn & Yahr Stage 1 or 2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Awards & highlights

PDWM Trial Summary

This trial will explore if a working memory training program can help improve cognitive and behavioural functions in early Parkinson's Disease patients taking medication.

Who is the study for?

This trial is for early-stage Parkinson's disease patients who feel their working memory isn't good or have clinically identified memory issues. They must be on a consistent dose of dopaminergic therapy and not have dementia, other major neurological conditions, or severe psychiatric disorders.Check my eligibility

What is being tested?

The study tests if working memory training can help with cognitive functions in Parkinson's patients taking dopamine drugs. Participants will try different types of memory tasks to see which might improve their brain function.See study design

What are the potential side effects?

Since the interventions involve non-medical tasks focused on working memory training, there are no direct medical side effects expected from participating in this study.

PDWM Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with Parkinson's disease without a known cause.

Select...

My Parkinson's disease is in the early stages.

Select...

I am on a consistent dose of medication for dopamine regulation.

PDWM Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 22 weeks post training onset

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~22 weeks post training onset

This trial's timeline: 3 weeks for screening, Varies for treatment, and 22 weeks post training onset for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Baseline Working memory function

Change in working memory function between baseline and 10 weeks post training onset

Change in working memory function between baseline and 22 weeks post training onset

+1 more

Secondary outcome measures

Baseline Executive functioning

Baseline fluid intelligence

Change in executive function between baseline and 22 weeks post training onset

+5 more

PDWM Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: Late training groupExperimental Treatment2 Interventions

The late training group will consist of 10 randomly assigned participants who will engage in a non-adaptive working memory training task (i.e. an active control task) immediately after baseline assessment for 5 weeks. After the initial 5 weeks of the active control task they will then switch to the adaptive working memory task (the intervention) for 5 weeks. This is a randomized controlled cross-over design.

Group II: Early training groupExperimental Treatment2 Interventions

The early training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. They will continue training on the adaptive working memory training task for 5 weeks, after which they will continue for 5 weeks using a non-adaptive working memory task (active control task).

Group III: No training groupPlacebo Group1 Intervention

The no training group will engage in no training over the course of the pilot study, but will still participate in baseline, 5 week, 10 . This will allow us to determine if changes in the outcome and assessment variables are due to the working memory training or progression in the disease itself.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Gail EskesLead Sponsor

Nova Scotia Health AuthorityOTHER

258 Previous Clinical Trials

83,824 Total Patients Enrolled

Gail Eskes, PhDStudy DirectorDalhousie University

Media Library

Adaptive working memory training task Clinical Trial Eligibility Overview. Trial Name: NCT01647698 — N/A

Parkinson's Disease Research Study Groups: Late training group, No training group, Early training group

Parkinson's Disease Clinical Trial 2023: Adaptive working memory training task Highlights & Side Effects. Trial Name: NCT01647698 — N/A

Adaptive working memory training task 2023 Treatment Timeline for Medical Study. Trial Name: NCT01647698 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the recruitment phase of this trial currently underway?

"Information found on clinicaltrials.gov makes it clear that this particular study is not actively recruiting participants at present, even though the trial was created in October 2013 and last updated in December 2021. Nevertheless, there are an abundance of 514 other medical trials seeking enrolment right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pilot Study to Determine if Working Memory Training Aids Cognitive Functioning in Patients With Parkinson's Disease

Gail Eskes 2013. "Pilot Study to Determine if Working Memory Training Aids Cognitive Functioning in Patients With Parkinson's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01647698.

All > Memory > Aids